Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors

SUMMARY

N/A

COH Protocol Number : 15173

ClinicalTrials.gov Number : NCT02482168

Principal Investigator : Fakih, Marwan M.D.

Sponsor : Apexigen, Inc.

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:1

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :